Tumor ‘Paint’ Aids Breast Cancer Surgeons and Well-Tolerated by Patients, Study Reports

Tumor ‘Paint’ Aids Breast Cancer Surgeons and Well-Tolerated by Patients, Study Reports
BLZ-100 (tozuleristide) was found to be well-tolerated by patients and to make breast cancer tumors more easily seen during surgery in a Phase 1 clinical trial, Blaze Bioscience announced. BLZ-100 was used to “paint” tumors to better guide surgeons while operating. Results of the trial (NCT02496065) were presented at the American Society of Breast Surgeons annual meeting in Las Vegas, Nevada, last month. BLZ-100 is a drug that consists of a dye that emits light in the near-infrared range, and an "optide," or kind of peptide, a small chemical that specifically attaches to solid tumors, “painting” them with dye so that they can be easily seen. The ability to see cancer cells during surgery should make tumor detection more accurate and allow for more precise and complete surgical removal of cancer — while sparing surrounding normal tissue. It is the first in a line of product candidates in Blaze’s Tumor Paint platform. The study included 23 patients with breast cancer that was either invasive (spread within the breast) or limited to one location, and was found to be well-tolerated. The drug's ability to outline tumors was shown, supporting BLZ-100 as a visual aid in detecting breast cancer sites. Participants received one of two dose levels, and safety data — along with clinical proof that BLZ-100 can detect breast cancer in the laboratory after tissue is removed and during surgery — were documented. BLZ-100 is also being tested in gliomas (a kind of brain cancer), central nervous sy
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.